RPL18 and neoplasm: Finally, while therapeutic vaccination using mutated Adpgk or Rpl18 peptides already reduced MC-38 tumor growth,43,46 therapeutic efficacy was further improved when these MHC class I-binding peptides were combined with MHC class II-binding peptides Zmiz1, Pcdh18, and Ddr2.48